Study name | Uninfected | HCV, HBV, or co-infection | Reference | ||||
Responses | Total treated | ORR | Responses | Total treated | ORR | ||
Nivolumab (CheckMate 040) | 25 | 113 | 0.221 | 17 | 101 | 0.168 | El-Khoueiry AB et al 1 |
Nivolumab+ipilimumab Checkmate 040 | 5 | 33 | 0.152 | 36 | 108 | 0.333 | Yau T et al
40 |
Pembrolizumab (Keynote 224) | 13 | 64 | 0.203 | 5 | 39 | 0.128 | Zhu AX et al 2 |
Durvalumab+tremelimumab | 6 | 20 | 0.3 | 0 | 20 | 0 | Kelley RK et al 41 |
Durvalumab | 2 | 22 | 0.091 | 2 | 18 | 0.111 | Wainberg ZA et al 42 |
Pembrolizumab | 4 | 17 | 0.235 | 5 | 12 | 0.417 | Feun LG et al 43 |
HBV, hepatitis B virus; HCV, hepatitis C virus; ORR, objective response rate.